Pira11 inhibitors encompass a variety of compounds that interact with specific cellular signaling pathways to reduce the activity of this protein. LY294002 and Wortmannin are two such inhibitors that target the phosphoinositide 3-kinases (PI3K) pathway, which is critical for the regulation of various cellular processes. By inhibiting PI3K, these compounds prevent the downstream activation of Akt, a serine/threonine-specific protein kinase that plays a role in multiple cellular processes including glucose metabolism, apoptosis, cell proliferation, and transcription. If Pira11 activity is mediated through PI3K/Akt signaling, the application of LY294002 or Wortmannin would result in the attenuation of its functional activity. Similarly, Rapamycin and PP242 directly inhibit the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth and proliferation. Inhibition of mTOR through these compounds could lead to decreased Pira11 activity if it is associated with mTOR signaling.
Further expanding on the arsenal of Pira11 inhibitors, SB203580 and PD98059 specifically target the p38 MAP kinase and MEK/ERK pathways, respectively. These inhibitors would lead to a reduction in Pira11 activity by blocking the pathways that are critical for responding to stress stimuli and proliferative signals. Additionally, SP600125 and U0126 are inhibitors that reduce the activity of JNK and MEK, which could indirectly lower Pira11 function if it is regulated by these kinases. ZM336372 and Dasatinib serve to inhibit the RAF kinase and Src kinase pathways, which are important for cell growth and differentiation. If Pira11 is regulated through these pathways, its activity would be impeded by these inhibitors. Lastly, NF449 and AG490 are selective inhibitors targeting the P2X purinergic receptors and JAK/STAT pathway, respectively. These inhibitors would decrease the activity of Pira11 by preventing the signal transduction events typically mediated by these receptors and kinases, assuming Pira11's activity is dependent on these signaling mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which decreases Akt phosphorylation and activity. Inhibition of this pathway would reduce Pira11 activity if Pira11 is downstream of PI3K/Akt signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that would lead to reduced activity of Pira11 by blocking the PI3K-dependent signaling pathways involved in cell survival and proliferation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAP kinase, which could decrease Pira11 function if Pira11 is modulated by the p38 MAPK signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
It specifically binds to mTOR complex and inhibits its activity. If Pira11 is involved in the mTOR signaling pathway, the use of Rapamycin would reduce its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which would prevent the activation of ERK. If Pira11 is regulated by the MEK/ERK pathway, PD98059 would decrease its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway, which could lower Pira11 activity if it is regulated by JNK-mediated cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A well-known MEK inhibitor that would indirectly decrease Pira11 activity by inhibiting ERK phosphorylation if Pira11 operates within this pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
A selective mTOR kinase inhibitor that would reduce Pira11 activity if Pira11 is part of the mTOR signaling cascade. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
A potent RAF kinase inhibitor that would decrease Pira11 function if Pira11 is regulated through the RAF/MEK/ERK signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src kinase inhibitor that would impair Pira11 activity if Pira11 is involved in Src-related signaling mechanisms. | ||||||